December 4, 2017.
Hummingbird Bioscience, a
preclinical -stage drug development company focused on novel cancer immuno-therapeutics,
will present a poster “HMBD-004A, a Novel Anti-CD47xCD33 Bispecific Antibody
Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML” at the 59th
American Society of Hematology (ASH) Annual Meeting in Atlanta on 9th
HMBD-004A is a bispecific antibody
targeting CD47 and CD33, developed using Hummingbird’s proprietary Rational
Antibody Discovery platform.
CD47 is the “don’t-eat-me” signal,
ubiquitously expressed on normal cells, and is over-expressed 5-10 fold on AML
cells. Anti-CD47 therapies have shown
promising anti-tumor efficacy in both preclinical and clinical studies. However
the widespread expression of CD47 decreases the bioavailability of anti-CD47 antibodies
at the tumor, while the high expression of CD47 on red blood cells also
presents a safety risk.
Through simultaneous binding of CD33, which
is significantly over-expressed on AML cells, HMBD-004A achieves increased specificity
for tumor cells, while reducing the risk of cross-linking red blood cells.
HMBD-004A has demonstrated excellent efficacy and safety in pre-clinical models.
The poster will be presented on Saturday,
December 9, 2017, 5:30 PM-7:30 PM in Hall A2 of the Georgia World Congress
In addition, Hummingbird has today
announced that it has signed a Research Evaluation Agreement with Genmab to access
the DuoBody® bispecific technology platform to further the development of
For further information please email CEO Piers Ingram: email@example.com
Hummingbird Bioscience is an innovative
biotechnology company, harnessing the potential of integrative biology to
discover and develop novel cancer immuno-therapeutics. We are focused on taking projects from
validated target to clinical proof of concept. Our data and model driven
integrative biology approach provide an unprecedented ability to understand and
manipulate the immune system – allowing us to 1) Identify the right targets and
mechanisms 2) Generate best in class antibodies against these targets 3)
Characterize the effect of our drug candidates on the tumor and immune system
at a molecular and cellular level, to better predict clinical outcomes of our
drugs. We have compelling pre-clinical
data for four potential first in class therapeutic programs focused on the most
exciting targets in oncology.
Genmab and its DuoBody® Platform
Genmab is an international biotechnology
company specializing in the creation and development of differentiated antibody
therapeutics for the treatment of cancer.
Genmab’s DuoBody platform is an innovative platform for the discovery
and development of bispecific antibodies. DuoBody molecules are unique in
combining the benefits of bispecificity with the strengths of conventional
antibodies which allows DuoBody molecules to be administered and dosed as other
antibody therapeutics. Genmab's DuoBody platform generates bispecific
antibodies via a fast and broadly applicable process which is easily performed
at standard bench, as well as commercial, manufacturing scale.